U.S. market Closed. Opens in 1 day 9 hours 21 minutes

LVTX | LAVA Therapeutics N.V. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue6.77M19.39M5.35M3.75MN/A
Cost of Revenue3.48MN/AN/A15.70M8.35M
Gross Profit3.29M19.39M5.35M-11.95M-8.35M
Operating Expenses46.54M51.31M46.92M3.59M1.25M
Selling, General & Admin12.73M14.12M12.02M2.72M1.24M
Research & Development33.81M40.10M36.95M15.70M8.35M
Other Operating ExpensesN/AN/AN/AN/AN/A
Operating Income-43.25M-34.84M-43.61M-14.67M-9.58M
Other Expenses / Income1.56M3.18M1.42M-1.21M-104.00K
Before Tax Income-41.70M-31.66M-42.20M-15.88M-9.69M
Income Tax Expenses279.00K249.00K157.00K43.00KN/A
Net Income-41.97M-31.91M-42.35M-15.93M-9.69M
Interest ExpensesN/AN/A625.00K342.00KN/A
Basic Shares Outstanding26.73M25.92M19.76M25.35M18.41M
Diluted Shares Outstanding26.73M25.92M19.76M25.35M18.41M
EBITDA-40.42M-30.88M-41.02M-14.65M-9.48M
EBITDA Margin-597.09%-159.23%-766.64%-391.04%0.00%
EBIT-41.70M-31.66M-41.57M-15.54M-9.69M
EBIT Margin-615.97%-163.26%-777.07%-414.79%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙